| Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, ... Cell 184 (3), 596-614. e14, 2021 | 581 | 2021 |
| Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Y Chu, E Dai, Y Li, G Han, G Pei, DR Ingram, K Thakkar, JJ Qin, M Dang, ... Nature medicine 29 (6), 1550-1562, 2023 | 78 | 2023 |
| Pharmacologic modulation of nonsense-mediated decay induces anti-tumor immunogenicity in ex vivo patient tumors R Vendramin, H Fu, Y Zhao, S Fernandez-Patel, D Qian, L Ligammari, ... Cancer Research 84 (6_Supplement), 6737-6737, 2024 | | 2024 |
| Drivers of immunotherapy response within the CPI3000+ cohort K Thakkar, A Castro, D Qian, C Swanton, K Litchfield Cancer Research 84 (6_Supplement), 2507-2507, 2024 | | 2024 |
| Targeting the nonsense mediated mRNA decay pathway to prevent the degradation of highly immunogenic frameshift mutated transcripts SF Patel, R Vendramin, D Qian, Y Zhao, L Ligammari, K Thakkar, J Murai, ... Cancer Research 84 (6_Supplement), 5625-5625, 2024 | | 2024 |
| Identifying new immunotherapy targets using machine learning and ex vivo validation M Augustine, NR Nene, K Thakkar, D Qian, E Fitzsimons, BS Simpson, ... Cancer Research 84 (6_Supplement), 5887-5887, 2024 | | 2024 |
| 1O Uncovering new immunotherapy targets with machine learning and ex vivo validation M Augustine, NR Nene, K Thakkar, D Qian, E Fitzsimons, C Pinder, H Fu, ... ESMO Open 9, 2024 | | 2024 |
| 142P Identifying novel immunotherapy targets using machine learning and ex vivo validation M Augustine, NR Nene, K Thakkar, D Qian, E Fitzsimons, B Simpson, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| 41P Contrasting drivers of response to immunotherapy across solid tumour types: Results from analysis of> 2500 cases D Qian, K Thakkar, A Castro, C Swanton, KR Litchfield Immuno-Oncology and Technology 20, 2023 | | 2023 |
| Whole-genome sequencing uncovers the genomic determinants of therapeutic resistance to immune checkpoint blockade K Litchfield, B Simpson, H Cha, A Castro, R Bentham, L Ryan, M Dietzen, ... | | 2023 |
| Quantifying the impact of immunotherapy on RNA dynamics in cancer I Usaite, D Biswas, K Dijkstra, TBK Watkins, O Pich, C Puttick, M Angelova, ... Journal for Immunotherapy of Cancer 11 (11), 2023 | | 2023 |
| 7P PrimeCUTR: Identifying clinically relevant neoantigens in the untranslated regions of cancer genomes CC Sng, BS Simpson, J Van De Haar, H Cha, A Coulton, K Thakkar, ... Immuno-Oncology and Technology 16, 2022 | | 2022 |
| Exploring the microbial landscape of NSCLC through TRACERx K Thakkar, H Fu, S Veeriah, K Litchfield, C Swanton, ... Cancer Research 82 (12_Supplement), 3043-3043, 2022 | | 2022 |
| Non-classical sources of tumour specific antigen in checkpoint inhibitor response K Thakkar, D Qian, H Cha, TB Watkins, C Swanton, K Litchfield Cancer Research 82 (12_Supplement), 643-643, 2022 | | 2022 |
| Cancer Associated Bacteria in Primary and Metastatic Non-Small Cell Lung Cancer K Thakkar, C Richard, H Fu, BS Simpson, H Cha, M Augustine, A Coulton, ... | | |
| Pharmacologic Inhibition of Nonsense-Mediated Decay Induces Anti-Tumour Immunogenicity in Ex Vivo Patient Tumours R Vendramin, H Fu, Y Zhao, S Fernandez Patel, D Qian, L Ligammari, ... | | |
| A Pan-Cancer Single-Cell RNA-Seq Atlas of Intratumoral B Cells E Fitzsimons, K Thakkar, M Augustine, A Enica, D Qian, J Reading, ... Available at SSRN 4663949, 0 | | |
